Physicians' Academy for Cardiovascular Education

Update of ACC Expert consensus decision pathway on management of atherosclerotic CVD risk

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk

A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways - Endorsed by the National Lipid Association

Sep. 20, 2017 - news

New data from the FOURIER and the SPIRE-1 and -2 studies with PCSK9 inhibitors led to an update of the 2016 ACC consensus paper on the role of non-statin therapies for LDL-C lowering in the management of atherosclerotic CV disease (ASCVD) risk. The aim of the update is to answer the following questions regarding the use of non-statin therapies:

The main changes to the 2016 consensus paper are the following:

The 2017 update of the 2016 consensus paper addresses current gaps in care for LDL-C lowering to reduce ASCVD risk. The algorithms endorse the 4 evidence-based statin benefit groups identified in the 2013 ACC/AHA cholesterol guidelines and assume that the patient is currently taking or has attempted to take a statin, given that this is the most effective initial therapy. The 4 evidence-based statin benefit groups are:

Find the full focused update at J Am Coll Cardiol